EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mitochondrial Dysfunction in Pulmonary Hypertension

Gusty Rizky Teguh Ryanto iD, Ratoe Suraya, Tatsuya Nagano iD

Antioxidants · 03.02.2023 · 12 (2) · 372

DOI: 10.3390/antiox12020372 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 03.02.2023. Verfasst von Gusty Rizky Teguh Ryanto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, Kobe 658-8558, Japan. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary hypertension (PH) is a multi-etiological condition with a similar hemodynamic clinical sign and end result of right heart failure. Although its causes vary, a similar link across all the classifications is the presence of mitochondrial dysfunction. Mitochondria, as the powerhouse of the cells, hold a number of vital roles in maintaining normal cellular homeostasis, including the pulmonary vascular cells. As such, any disturbance in the normal functions of mitochondria could lead to major pathological consequences. The Warburg effect has been established as a major finding in PH conditions, but other mitochondria-related metabolic and oxidative stress factors have also been reported, making important contributions to the progression of pulmonary vascular remodeling that is commonly found in PH pathophysiology. In this review, we will discuss the role of the mitochondria in maintaining a normal vasculature, how it could be altered during pulmonary vascular remodeling, and the therapeutic options available that can treat its dysfunction.

Schlagwörter

Stichwörter der Autor:innen

Warburg effectmitochondrial dysfunctionoxidative stresspulmonary hypertensionpulmonary vascular remodeling

Autor:innen und Institutionen

  • Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, Kobe 658-8558, Japan.
  • Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.

ORCID-Profile: Gusty Rizky Teguh Ryanto, Tatsuya Nagano

Zitieren

APA

Ryanto, G. R. T., Suraya, R., & Nagano, T. (2023). Mitochondrial Dysfunction in Pulmonary Hypertension. Antioxidants, 12(2), 372. https://doi.org/10.3390/antiox12020372

Vancouver

Ryanto GRT, Suraya R, Nagano T. Mitochondrial Dysfunction in Pulmonary Hypertension. Antioxidants. 2023;12(2):372. doi:10.3390/antiox12020372

BibTeX
@article{Ryanto2023,
  author = {Ryanto, Gusty Rizky Teguh and Suraya, Ratoe and Nagano, Tatsuya},
  title = {Mitochondrial Dysfunction in Pulmonary Hypertension},
  journal = {Antioxidants},
  year = {2023},
  volume = {12},
  number = {2},
  pages = {372},
  doi = {10.3390/antiox12020372}
}
Kostenlos starten →